Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target dropped by HC Wainwright from $22.00 to $12.00 in a note issued to investors on Friday,Benzinga reports. The brokerage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback